340 related articles for article (PubMed ID: 10640759)
1. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
[TBL] [Abstract][Full Text] [Related]
2. Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.
De Pascalis R; Iwahashi M; Tamura M; Padlan EA; Gonzales NR; Santos AD; Giuliano M; Schuck P; Schlom J; Kashmiri SV
J Immunol; 2002 Sep; 169(6):3076-84. PubMed ID: 12218124
[TBL] [Abstract][Full Text] [Related]
3. In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants.
De Pascalis R; Gonzales NR; Padlan EA; Schuck P; Batra SK; Schlom J; Kashmiri SV
Clin Cancer Res; 2003 Nov; 9(15):5521-31. PubMed ID: 14654532
[TBL] [Abstract][Full Text] [Related]
4. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.
Iwahashi M; Milenic DE; Padlan EA; Bei R; Schlom J; Kashmiri SV
Mol Immunol; 1999; 36(15-16):1079-91. PubMed ID: 10698310
[TBL] [Abstract][Full Text] [Related]
5. Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.
Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
Mol Immunol; 2003 Oct; 40(6):337-49. PubMed ID: 14522015
[TBL] [Abstract][Full Text] [Related]
6. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
Kashmiri SV; Shu L; Padlan EA; Milenic DE; Schlom J; Hand PH
Hybridoma; 1995 Oct; 14(5):461-73. PubMed ID: 8575795
[TBL] [Abstract][Full Text] [Related]
7. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.
Kashmiri SV; Iwahashi M; Tamura M; Padlan EA; Milenic DE; Schlom J
Crit Rev Oncol Hematol; 2001 Apr; 38(1):3-16. PubMed ID: 11255077
[TBL] [Abstract][Full Text] [Related]
8. SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.
Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
Mol Immunol; 2004 Jul; 41(9):863-72. PubMed ID: 15261458
[TBL] [Abstract][Full Text] [Related]
9. SDR grafting--a new approach to antibody humanization.
Kashmiri SV; De Pascalis R; Gonzales NR; Schlom J
Methods; 2005 May; 36(1):25-34. PubMed ID: 15848072
[TBL] [Abstract][Full Text] [Related]
10. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.
Mateo C; Moreno E; Amour K; Lombardero J; Harris W; Pérez R
Immunotechnology; 1997 Mar; 3(1):71-81. PubMed ID: 9154469
[TBL] [Abstract][Full Text] [Related]
11. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28.
Tan P; Mitchell DA; Buss TN; Holmes MA; Anasetti C; Foote J
J Immunol; 2002 Jul; 169(2):1119-25. PubMed ID: 12097421
[TBL] [Abstract][Full Text] [Related]
12. Elimination of the immunogenicity of therapeutic antibodies.
Gilliland LK; Walsh LA; Frewin MR; Wise MP; Tone M; Hale G; Kioussis D; Waldmann H
J Immunol; 1999 Mar; 162(6):3663-71. PubMed ID: 10092828
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct.
Pavlinkova G; Colcher D; Booth BJ; Goel A; Batra SK
Cancer Immunol Immunother; 2000 Jul; 49(4-5):267-75. PubMed ID: 10941910
[TBL] [Abstract][Full Text] [Related]
14. Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas.
Mersmann M; Schmidt A; Rippmann JF; Wüest T; Brocks B; Rettig WJ; Garin-Chesa P; Pfizenmaier K; Moosmayer D
Int J Cancer; 2001 Apr; 92(2):240-8. PubMed ID: 11291052
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments.
Ichiyoshi Y; Casali P
J Exp Med; 1994 Sep; 180(3):885-95. PubMed ID: 8064239
[TBL] [Abstract][Full Text] [Related]
16. Analysis of antigen binding and idiotypic expression by antibodies with polyglycine-replaced complementarity-determining regions.
Sompuram SR; Den W; Sharon J
J Immunol; 1996 Feb; 156(3):1071-81. PubMed ID: 8557981
[TBL] [Abstract][Full Text] [Related]
17. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
18. Cloning of cDNAs encoding the variable domains of antibody KC4G3 and construction of a chimeric antibody.
Couto JR; Blank EW; Peterson JA; Ceriani RL
Hybridoma; 1993 Aug; 12(4):485-9. PubMed ID: 8244420
[TBL] [Abstract][Full Text] [Related]
19. Gangliosides, Ab1 and Ab2 antibodies II. Light versus heavy chain: An idiotype-anti-idiotype case study.
López-Requena A; Rodríguez M; de Acosta CM; Moreno E; Puchades Y; González M; Talavera A; Valle A; Hernández T; Vázquez AM; Pérez R
Mol Immunol; 2007 Feb; 44(5):1015-28. PubMed ID: 16620986
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody.
Graves SS; Goshorn SC; Stone DM; Axworthy DB; Reno JM; Bottino B; Searle S; Henry A; Pedersen J; Rees AR; Libby RT
Clin Cancer Res; 1999 Apr; 5(4):899-908. PubMed ID: 10213227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
